利妥昔单抗联合糖皮质激素治疗天疱疮的短期预后因素:多中心回顾性研究
这项多中心回顾性研究纳入276例接受初始利妥昔单抗联合糖皮质激素治疗的天疱疮患者,评估52周结局。52周时134例(48.6%)达到最小治疗下完全缓解,35例(12.7%)复发。独立预测因素包括:3次利妥昔单抗输注、较高基线IgM水平和无基线HSV感染预测完全缓解;较高体重、既往免疫抑制剂使用和既往环磷酰胺使用预测复发。不良事件发生率23.2%,主要为感染,各预后亚组间无显著差异。
要点
- 3次RTX输注、较高基线IgM、无基线HSV感染预测52周CR mini。
- 较高体重、既往免疫抑制剂或环磷酰胺使用预测复发。
- 不良事件率23.2%,主要为感染,预后亚组间无显著差异。
核心结论
- 研究识别了RTX治疗天疱疮中CR mini和复发的易获取基线预测因素,有助于早期风险分层和个体化治疗。
研究设计与样本
- 多中心回顾性研究,纳入276例接受初始RTX联合糖皮质激素治疗的天疱疮患者,采用单因素和多因素logistic回归分析。
主要发现
- 52周内134例(48.6%)达到CR mini,35例(12.7%)复发。
- CR mini独立预测因素:3次RTX输注、较高基线IgM水平、无基线HSV感染。
- 复发独立预测因素:较高体重、既往免疫抑制剂使用、既往环磷酰胺使用。
- 不良事件发生率23.2%,主要为感染,各预后亚组间无显著差异。
关键数值与推荐
- CR mini:最小治疗下完全缓解,52周累积48.6%。
- 复发:52周累积12.7%。
- 不良事件:23.2%,主要为感染。
临床怎么用
- 可依据3次RTX输注、基线IgM水平及基线HSV感染状态早期识别CR mini可能较高的患者。
- 对较高体重、有既往免疫抑制剂或环磷酰胺使用史者应加强复发监测。
局限性
- 回顾性设计。
- 缺乏动态生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rituximab (RTX), combined with glucocorticoids, is a first-line treatment for pemphigus, yet short-term prognostic outcomes and their predictors remain underexplored in Chinese populations. OBJECTIVE: To evaluate the 52-week outcomes of RTX combined with glucocorticoids in a real-world Chinese cohort and identify independent predictors of complete remission on minimal therapy (CR mini) and relapse. METHODS: This multicenter retrospective study included 276 pemphigus patients who received initial RTX combined with glucocorticoids. Univariate and multivariate logistic regression analyses were performed to identify predictors of CR mini and relapse. RESULTS: Over 52 weeks, 134 (48.6%) patients achieved CR mini, and 35 (12.7%) relapsed. Independent predictors for CR mini were 3 RTX infusions, higher baseline immunoglobulin M level and absence of baseline herpes simplex virus infection. For relapse, independent predictors were higher body weight, prior immunosuppressant use, and prior cyclophosphamide use. Adverse events occurred in 23.2% of patients, primarily infections, with no significant differences across prognostic subgroups. LIMITATIONS: Retrospective design and absence of dynamic biomarkers. CONCLUSION: This study identifies readily obtainable baseline predictors for CR mini and relapse in RTX-treated pemphigus, facilitating early risk stratification and individualized treatment strategies to optimize long-term outcomes.
引用
- Wu Z, Jiang J, Chen S, et al. Short-term prognostic factors of rituximab combined with glucocorticoids in the treatment of pemphigus: A multicenter retrospective study. J Am Acad Dermatol. 2026. PMID: 42749058. doi:10.1016/j.jaad.2026.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。